JNJ-79635322

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for JNJ-79635322, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

See pricing